Hostname: page-component-78c5997874-mlc7c Total loading time: 0 Render date: 2024-11-14T16:26:48.558Z Has data issue: false hasContentIssue false
  • English
  • Français

Purified chick embryo cell rabies vaccine: economical multisite intradermal regimen for post-exposure prophylaxis

Published online by Cambridge University Press:  19 October 2009

Pravan Suntharasamai ,
M. J. Warrell ,
Chaisin Viravan ,
Pornthep Chanthavanich ,
Sornchai Looareesuwan ,
Achara Supapochana ,
Juntra Karbwang Wichai Supanaranond ,
Sunee Chittamas ,
U. Bijok  and
D. A. Warrell
Pravan Suntharasamai
Affiliation:
Hospital for Tropical Diseases, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Sir William Dunn School of Pathology and Nuffield Department of Clinical Medicine, Oxford University, U.K., and Behring Research Laboratories, Marburg, West Germany
M. J. Warrell
Affiliation:
Hospital for Tropical Diseases, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Sir William Dunn School of Pathology and Nuffield Department of Clinical Medicine, Oxford University, U.K., and Behring Research Laboratories, Marburg, West Germany
Chaisin Viravan
Affiliation:
Hospital for Tropical Diseases, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Sir William Dunn School of Pathology and Nuffield Department of Clinical Medicine, Oxford University, U.K., and Behring Research Laboratories, Marburg, West Germany
Pornthep Chanthavanich
Affiliation:
Hospital for Tropical Diseases, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Sir William Dunn School of Pathology and Nuffield Department of Clinical Medicine, Oxford University, U.K., and Behring Research Laboratories, Marburg, West Germany
Sornchai Looareesuwan
Affiliation:
Hospital for Tropical Diseases, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Sir William Dunn School of Pathology and Nuffield Department of Clinical Medicine, Oxford University, U.K., and Behring Research Laboratories, Marburg, West Germany
Achara Supapochana
Affiliation:
Hospital for Tropical Diseases, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Sir William Dunn School of Pathology and Nuffield Department of Clinical Medicine, Oxford University, U.K., and Behring Research Laboratories, Marburg, West Germany
Juntra Karbwang Wichai Supanaranond
Affiliation:
Hospital for Tropical Diseases, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Sir William Dunn School of Pathology and Nuffield Department of Clinical Medicine, Oxford University, U.K., and Behring Research Laboratories, Marburg, West Germany
Sunee Chittamas
Affiliation:
Hospital for Tropical Diseases, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Sir William Dunn School of Pathology and Nuffield Department of Clinical Medicine, Oxford University, U.K., and Behring Research Laboratories, Marburg, West Germany
U. Bijok
Affiliation:
Hospital for Tropical Diseases, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Sir William Dunn School of Pathology and Nuffield Department of Clinical Medicine, Oxford University, U.K., and Behring Research Laboratories, Marburg, West Germany
D. A. Warrell
Affiliation:
Hospital for Tropical Diseases, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Sir William Dunn School of Pathology and Nuffield Department of Clinical Medicine, Oxford University, U.K., and Behring Research Laboratories, Marburg, West Germany
Rights & Permissions [Opens in a new window]

Summary

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

The standard six-dose intramuscular (i.m.) rabies post-exposure vaccine regimen using a new purified chick embryo cell (PCEC) vaccine was compared with two economical multisite intradermal (i.d.) PCEC regimens, a multisite i.m. PCEC schedule and a subcutaneous regimen using a suckling mouse brain (SMB) rabies vaccine manufactured in Thailand. The neutralizing antibody results for the four-site and eight-site i.d. and the standard i.m. PCEC regimens were similar over 3 months. A three-site i.m. PCEC regimen had no advantage. The SMB vaccine gave the lowest antibody levels. Human rabies immune globulin therapy significantly increased the GMT of all groups on day 7, unlike equine antirabies serum (EARS). Both antisera suppressed antibody responses to PCEC on days 14 and 28. Three generalized reactions probably related to EARS were the only serious side effects. An eight-site i.d. PCEC vaccine regimen proved as immunogenic as the routine i.m. schedule and, if implemented as post-exposure prophylaxis, would be the cheapest widely available tissue culture vaccine regimen. The protective efficiency should now be tested in patients bitten by rabid animals.

Type
Research Article
Information
Epidemiology & Infection , Volume 99 , Issue 3 , December 1987 , pp. 755 - 765
Copyright
Copyright © Cambridge University Press 1987

References

REFERENCES

Barth, R., Gruschkau, H., Bijok, U., Hilfenhaus, J., Hinz, J., Milcke, L., Moser, H., Jaegar, O., Ronneberoer, H. & Weinmann, E. (1984). A new inactivated tissue culture rabies vaccine for use in man. Evaluation of PCEC vaccine by laboratory tests. Journal of Biological Standardization 12, 29–46.CrossRefGoogle ScholarPubMed
Bijok, U. (1985). Purified chick embryo cell (PCKC) rabies vaccine: a review of the clinical development 1982–1984. In Improvements in Babies Post-Exposure Treatment (ed. Vodopija, T., Nicholson, K. G., Smerdal, S. and Bijok, U.), pp. 103–111. Zagreb: Zagreb Institute of Public Health.Google Scholar
Bijok, U., Vodopija, I., Smerdel, S., Thonocharoen, P., Nicholson, K., Dietrich, M. & Gonzalez de Cosio, A. (1984). Purified chick embryo cell (PCEC) rabies vaccine for human use: clinical trials. Behring Instihit Mitteilungen 76, 155–164.Google Scholar
Centers for Disease Control (1984). Recommendation of the immunization practices advisory committee. Rabies prevention – United States, 1984. Morbidity and Mortality Weekly Report 33, 393–408.Google Scholar
Chanthavanich, P., Suntharasamai, P., Warrell, M. J., Viravan, C., Looareesuwan, S., Supanaranond, W., Karhwang, J., Warrell, D. A., Phillips, R. E.Sinhaseni, A., Boonyarataphan, P. & Sureau, P. (1987). Antibody response to suckling mouse brain rabies vaccines for post-exposure treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene 81, 260–263.CrossRefGoogle ScholarPubMed
Harverson, G. (1984). Post-exposure intradermal antirabies vaccine: a cheaper alternative for developing countries. Tropical Doctor 14, 67–70.CrossRefGoogle ScholarPubMed
Hattwick, A. W., Corey, L. & Creech, W. B. (1976). Clinical use of human globulin immune to rabies virus. Journal of Infectious Diseases 133 (suppl.), A266–272.Google Scholar
Helmick, C. G., Johnstone, C., Sumner, J., Winkler, W. G. & Fager, S. (1982). A clinical study of Méricux human rabies immune globulin. Journal of Biological Standardization 10, 357–367.Google Scholar
Hosty, T. S. & Hunter, F. R. (1953). Incidence of reactions to anti-rabies horse serum. Public Health Reports 68, 789–791.CrossRefGoogle Scholar
Karliner, J. S. & Belval, G. S. (1965). Incidence of reactions following administration of antirabies serum, study of 526 cases. Journal of the American Medical Association 193, 109–112.Google ScholarPubMed
Ljubičić, M., Vodopija, T., Smerdel, S., Baklaić, Ž., Svjetličić, M. & Lojkić, M. (1985). Efficacy of PCEC vaccine in post-exposure rabies prophylaxis. In Improvements in Rabies Post-Exposure Treatment (ed. Vodopija, I., Nicholson, K. G., Smerdel, S. and Bijok, U.), pp. 95–101. Zagreb: Zagreb Institute of Public Health.Google Scholar
Monson, M. H. (1985). Practical management of rabies and the 1982 outbreak in Zorzor district, Liberia. Tropical Doctor 15, 50–54.Google Scholar
Nicholson, K. G., Cole, P. J., Turner, G. S. & Harrison, P. (1979). Immune responses humans to a human diploid cell strain of rabies virus vaccine: lymphocyte transformation, production of virus-neutralizing antibody, and induction of interferon. Journal of Infectious Diseases 140, 176–182.CrossRefGoogle ScholarPubMed
Nicholson, K. G. & Turner, G. S. (1978). Studies with human diploid cells strain rabies vaccine and human antirabies immunoglobulin in man. Developments of Biological Standardization 40, 115–120.Google Scholar
Suntharasamai, P., Chanthavanich, P., Warrell, M. J., Looareesuwan, S., Karhwang, J., Supanaranond, W., Phillips, R. E., Jansawan, W., Xueref, C., Pouraimer-Duteil, X. & Warrell, D. A. (1986). Purified Vero cell rabies vaccine and human diploid cell strain vaccine: comparison of neutralizing antibody responses to post-exposure regimens. Journal of Hygiene 96, 483–489.CrossRefGoogle ScholarPubMed
Warrell, M. J., Nicholson, K. G., Warrell, D. A., Suntharasamai, P., Chanthavanich, P., Viravan, C., Sinilaseni, A., Chiewbamroonokiat, M., Pouradier-Duteil, X., C., Xueref, Phanfung, R. & Udomsakdi, D. (1985). Economical multiple-site intradermal immunisation with human diploid-cell-strain vaccine is effective for post-exposure rabies prophylaxis. Lancet i, 1059–1062.Google Scholar
Warrell, M. J., Suntharasamai, P., Nicholson, K. G., Warrell, D. A., Chanthavanich, P., Viravan, C., Sinilaseni, A., Phanfung, R., Xueref, C. & Vincent-Falquet, J.-C. (1984). Multisite intradermal and multisite subcutaneous rabies vaccination: improved economical regimens. Lancet i, 874–876.Google Scholar
Warrell, M. J., Warrell, D. A., Suntharasamai, P., Viravan, C., Sinhaseni, A., Udomsakdi, D., Phanfung, R., Xueref, C., Vincent-Falquet, J.-C., Nicholson, K. G., Bunnag, D. & Harinasuta, T. (1983). An economical regimen of human diploid cell strain antirabies vaccine for post-exposure prophylaxis. Lancet ii. 301–304.CrossRefGoogle Scholar
Wasi, C., Chaiprasithikul, P., Chavanich, L., Puthavathana, P., Thongcharoen, P. & Trishahananda, M. (1986). Purified chick embryo cell vaccine. Lancet i. 40.CrossRefGoogle Scholar
Wasi, C, Chaiprasithikul, P., Puthavathana, P., Chavanich, L. & Thongcharokn, P. (1985). Immunogenicity and reactogenicity of the new tissue culture rabies vaccine for human use (purified chick embryo cell culture). In Improvements in Rabies Post-Exposure Treatment (ed. Vodopija, T., Nicholson, K. G., Smerdel, S. and Bijok, U.). pp. 85–94. Zagreb: Zagreb Institute of Public Health.Google Scholar
Wasi, C., Chaiprasithikul, P., Thongcharoen, P., Rungpitarungsi, V., Tharachan, C. & Likanontsakul, S. (1983). Protective antibodies after vaccination with human diploid cell rabies vaccine. Asian Pacific Journal of Allergy and Immunology 1, 125–30.Google ScholarPubMed
Who Expert Committee on Rabies (1984). Seventh Report. Technical Report Series 709. pp. 28–31. Geneva: World Health Organization.Google Scholar